MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2018025874

Медицинская библиотека · Blood advances · 2019

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Jain Preetesh, Kantarjian Hagop, Boddu Prajwal C, Nogueras-González Graciela M, Verstovsek Srdan, Garcia-Manero Guillermo, Borthakur Gautam, Sasaki Koji, Kadia Tapan M, Sam Princy, Ahaneku Hycienth, O'Brien Susan, Estrov Zeev, Ravandi Farhad, Jabbour Elias, Cortes Jorge E

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated with frontline TKIs in different prospective trials: imatinib 400 mg (n = 71) and 800 mg (n = 203), nilotinib (n = 108), dasatinib (n = 106), and ponatinib (n = 43). Characteristics and incidence of new-onset CV-AEs and AT-AEs were analyzed. Poisson regression models assessed factors associated with AE incidence. Median follow-up was 94 months (range, 2-195). Overall, 237 patients (45%) developed CV-AEs and 46 (9%) developed AT-AEs. Hypertension was the most common AE seen in 175 patients (33%; grade 3/4 in 17%). CV-AE and AT-AE incidence ratios (IRs) with 95% confidence intervals (CIs) were 8.6 (7.6-9.8) and 1.7 (1.2-2.2) per 100 person-years. Among the TKIs, ponatinib showed the highest IR (95% CI) for CV-AEs and AT-AEs at 40.7 (27.9-59.4) and 9.0 (4.1-20.1). In multivariate analysis, ponatinib therapy was associated with increased incidence rate ratio (IRR) for CV-AEs (4.62; 95% CI, 2.7-7.7; P < .0001) and AT-AEs (6.38; 95% CI, 1.8-21.8; P < .0001) compared with imatinib 400. In summary, there is an increased risk of CV-AEs (except hypertension) and AT-AEs in CML patients treated with newer TKIs, particularly with ponatinib. Patients on TKIs must be informed and closely monitored for vascular AEs. These studies were registered at www.clinicaltrials.gov as #NCT00048672, #NCT00038649, #NCT00050531, #NCT00254423, #NCT00129740, and #NCT01570868.

Для цитирования: Jain Preetesh, Kantarjian Hagop, Boddu Prajwal C, Nogueras-González Graciela M, Verstovsek Srdan, Garcia-Manero Guillermo, Borthakur Gautam, Sasaki Koji, Kadia Tapan M, Sam Princy, Ahaneku Hycienth, O'Brien Susan, Estrov Zeev, Ravandi Farhad, Jabbour Elias, Cortes Jorge E. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.. Blood advances. 2019. DOI: 10.1182/bloodadvances.2018025874.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.